Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$117 Mln
P/E Ratio
--
P/B Ratio
10.94
Industry P/E
--
Debt to Equity
0.11
ROE
-41.48 %
ROCE
-1818.67 %
Div. Yield
0 %
Book Value
0.16
EPS
-0.51
CFO
$-286.66 Mln
EBITDA
$-305.69 Mln
Net Profit
$-310.22 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sellas Life Sciences Group Inc (SLS)
| 25.96 | 14.91 | 33.29 | -3.68 | -28.07 | -4.51 | -64.64 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Sellas Life Sciences Group Inc (SLS)
| -1.87 | -55.08 | -57.32 | -4.82 | 35.12 | -93.01 | -84.19 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.17 | 10,226.85 | 20.76 | 23.13 | |
| 296.24 | 9,219.66 | 24.15 | 58.42 | |
| 24.65 | 10,361.50 | -- | -28.77 | |
| 101.22 | 9,388.25 | 28.84 | 14.16 |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S... (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. Address: 7 Times Square, New York, NY, United States, 10036 Read more
Founder, President, CEO & Director
Dr. Angelos M. Stergiou M.D., ScD h.c.
Founder, President, CEO & Director
Dr. Angelos M. Stergiou M.D., ScD h.c.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sellas Life Sciences Group Inc (SLS) stood at $ 19 Mln as on 31-Dec-24
The share price of Sellas Life Sciences Group Inc (SLS) is $1.31 (NASDAQ) as of 17-Apr-2025 12:43 EDT. Sellas Life Sciences Group Inc (SLS) has given a return of -28.07% in the last 3 years.
Sellas Life Sciences Group Inc (SLS) has a market capitalisation of $ 117 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Sellas Life Sciences Group Inc (SLS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sellas Life Sciences Group Inc (SLS) and enter the required number of quantities and click on buy to purchase the shares of Sellas Life Sciences Group Inc (SLS).
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. Address: 7 Times Square, New York, NY, United States, 10036
The CEO & director of Dr. Angelos M. Stergiou M.D., ScD h.c.. is Sellas Life Sciences Group Inc (SLS), and CFO & Sr. VP is Dr. Angelos M. Stergiou M.D., ScD h.c..
There is no promoter pledging in Sellas Life Sciences Group Inc (SLS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Sellas Life Sciences Group Inc (SLS) | Ratios |
|---|---|
|
Return on equity(%)
|
-4147.88
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Sellas Life Sciences Group Inc (SLS) was $0 Mln.
$0.03
(
